Cargando…

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients

BACKGROUND: E1697 was a phase III trial of adjuvant interferon (IFN)-α2b for one month (Arm B) versus observation (Arm A) in patients with resected melanoma at intermediate risk. We evaluated the levels of candidate serum cytokines, the HLA genotype, polymorphisms of CTLA4 and FOXP3 genes and the de...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarhini, Ahmad A., Lin, Yan, Zahoor, Haris, Shuai, Yongli, Butterfield, Lisa H., Ringquist, Steven, Gogas, Helen, Sander, Cindy, Lee, Sandra, Agarwala, Sanjiv S., Kirwood, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508028/
https://www.ncbi.nlm.nih.gov/pubmed/26192408
http://dx.doi.org/10.1371/journal.pone.0132745
_version_ 1782381876744290304
author Tarhini, Ahmad A.
Lin, Yan
Zahoor, Haris
Shuai, Yongli
Butterfield, Lisa H.
Ringquist, Steven
Gogas, Helen
Sander, Cindy
Lee, Sandra
Agarwala, Sanjiv S.
Kirwood, John M.
author_facet Tarhini, Ahmad A.
Lin, Yan
Zahoor, Haris
Shuai, Yongli
Butterfield, Lisa H.
Ringquist, Steven
Gogas, Helen
Sander, Cindy
Lee, Sandra
Agarwala, Sanjiv S.
Kirwood, John M.
author_sort Tarhini, Ahmad A.
collection PubMed
description BACKGROUND: E1697 was a phase III trial of adjuvant interferon (IFN)-α2b for one month (Arm B) versus observation (Arm A) in patients with resected melanoma at intermediate risk. We evaluated the levels of candidate serum cytokines, the HLA genotype, polymorphisms of CTLA4 and FOXP3 genes and the development of autoantibodies for their association with relapse free survival (RFS) in Arm A and Arm B among 268 patients with banked biospecimens. METHODS: ELISA was used to test 5 autoantibodies. Luminex/One Lambda LABTypeRSSO was used for HLA Genotyping. Selected CTLA4 and FOXP3 Single nucleotide polymorphisms (SNPs) and microsatellites were tested for by polymerase chain reaction (PCR). Sixteen serum cytokines were tested at baseline and one month by Luminex xMAP multiplex technology. Cox Proportional Hazards model was applied and the Wald test was used to test the marginal association of each individual marker and RFS. We used the Lasso approach to select the markers to be included in a multi-marker Cox Proportional Hazards model. The ability of the resulting models to predict one year RFS was evaluated by the time-dependent ROC curve. The leave-one-out method of cross validation (LOOCV) was used to avoid over-fitting of the data. RESULTS: In the multi-marker modeling analysis conducted in Arm B, one month serum IL2Rα, IL-12p40 and IFNα levels predicted one year RFS with LOOCV AUC = 82%. Among the three markers selected, IL2Rα and IFNα were the most stable (selected in all the cross validation cycles). The risk score (linear combination of the 3 markers) separated the RFS curves of low and high risk groups well (p = 0.05). This model did not hold for Arm A, indicating a differential marker profile in Arm B linked to the intervention (adjuvant therapy). CONCLUSIONS: Early on-treatment proinflammatory serum markers (IL2Rα, IL-12p40, IFNα) significantly predict RFS in our cohort of patients treated with adjuvant IFN-α2b and warrant further study.
format Online
Article
Text
id pubmed-4508028
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45080282015-07-24 Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients Tarhini, Ahmad A. Lin, Yan Zahoor, Haris Shuai, Yongli Butterfield, Lisa H. Ringquist, Steven Gogas, Helen Sander, Cindy Lee, Sandra Agarwala, Sanjiv S. Kirwood, John M. PLoS One Research Article BACKGROUND: E1697 was a phase III trial of adjuvant interferon (IFN)-α2b for one month (Arm B) versus observation (Arm A) in patients with resected melanoma at intermediate risk. We evaluated the levels of candidate serum cytokines, the HLA genotype, polymorphisms of CTLA4 and FOXP3 genes and the development of autoantibodies for their association with relapse free survival (RFS) in Arm A and Arm B among 268 patients with banked biospecimens. METHODS: ELISA was used to test 5 autoantibodies. Luminex/One Lambda LABTypeRSSO was used for HLA Genotyping. Selected CTLA4 and FOXP3 Single nucleotide polymorphisms (SNPs) and microsatellites were tested for by polymerase chain reaction (PCR). Sixteen serum cytokines were tested at baseline and one month by Luminex xMAP multiplex technology. Cox Proportional Hazards model was applied and the Wald test was used to test the marginal association of each individual marker and RFS. We used the Lasso approach to select the markers to be included in a multi-marker Cox Proportional Hazards model. The ability of the resulting models to predict one year RFS was evaluated by the time-dependent ROC curve. The leave-one-out method of cross validation (LOOCV) was used to avoid over-fitting of the data. RESULTS: In the multi-marker modeling analysis conducted in Arm B, one month serum IL2Rα, IL-12p40 and IFNα levels predicted one year RFS with LOOCV AUC = 82%. Among the three markers selected, IL2Rα and IFNα were the most stable (selected in all the cross validation cycles). The risk score (linear combination of the 3 markers) separated the RFS curves of low and high risk groups well (p = 0.05). This model did not hold for Arm A, indicating a differential marker profile in Arm B linked to the intervention (adjuvant therapy). CONCLUSIONS: Early on-treatment proinflammatory serum markers (IL2Rα, IL-12p40, IFNα) significantly predict RFS in our cohort of patients treated with adjuvant IFN-α2b and warrant further study. Public Library of Science 2015-07-20 /pmc/articles/PMC4508028/ /pubmed/26192408 http://dx.doi.org/10.1371/journal.pone.0132745 Text en © 2015 Tarhini et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tarhini, Ahmad A.
Lin, Yan
Zahoor, Haris
Shuai, Yongli
Butterfield, Lisa H.
Ringquist, Steven
Gogas, Helen
Sander, Cindy
Lee, Sandra
Agarwala, Sanjiv S.
Kirwood, John M.
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
title Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
title_full Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
title_fullStr Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
title_full_unstemmed Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
title_short Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
title_sort pro-inflammatory cytokines predict relapse-free survival after one month of interferon-α but not observation in intermediate risk melanoma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508028/
https://www.ncbi.nlm.nih.gov/pubmed/26192408
http://dx.doi.org/10.1371/journal.pone.0132745
work_keys_str_mv AT tarhiniahmada proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT linyan proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT zahoorharis proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT shuaiyongli proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT butterfieldlisah proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT ringquiststeven proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT gogashelen proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT sandercindy proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT leesandra proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT agarwalasanjivs proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients
AT kirwoodjohnm proinflammatorycytokinespredictrelapsefreesurvivalafteronemonthofinterferonabutnotobservationinintermediateriskmelanomapatients